News
Axelar attends BIO Investor Forum in San Francisco, USA
17 October 2017
Axelar AB will attend the BIO Investor Forum in San Francisco, USA on October 17-18, 2017 to meet with potential partners and investors. The BIO Investor Forum is an international biotech investor conference focused on early and established private …
Axelar AB welcomes Vidar Wendel-Hansen as Chief Medical Officer
1 September 2017
Vidar Wendel-Hansen has more than twenty years’ experience from pre-clinical and clinical development. He has served as Medical Director in both small biotech and large pharmaceutical companies. Dr Wendel-Hansen is also former Clinical Assessor at …
FDA Grants Orphan Drug Designation for AXL1717 for the Treatment of Glioma
28 July 2017
Axelar AB, a pharmaceutical company focused on developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan …